Skip to content
DataLookout
Menu

CIRCLENCT07915505

Specific Immune Reconstitution After Allogeneic Transplantation and Letermovir Prophylaxis

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Eligibility criteria expanded, about 4 words
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Viral load of torque teno virus (TTV) in whole blood
Timeframe: Before transplantation (Day -30 to Day -8), Day 20, Month 3, Month 6, and Month 12 after transplantation.
Qualitative and functional assessment of natural killer (NK) cells
Timeframe: Before transplantation (Day -30 to Day -8) and Day 100 after transplantation in patients not receiving letermovir prophylaxis.
CMV-specific cellular immune response
Timeframe: Before transplantation (Day -30 to Day -8), Day 20, Month 3, Month 6, and one month after the end of letermovir prophylaxis, as applicable. An additional assessment will be performed one month after CMV reactivation, if applicable.
CMV-specific IgG concentration in plasma
Timeframe: Before transplantation (Day -30 to Day -8), Day 20, Month 3, Month 6, and one month after the end of letermovir prophylaxis, as applicable.
Time to development of a significant CMV-specific cellular immune response
Timeframe: From before transplantation (Day -30 to Day -8) through Month 12 after transplantation.
Number of participants with CMV infection
Timeframe: From before transplantation (Day -30 to Day -8) through Month 24 after transplantation.
Number of participants with CMV disease
Timeframe: From before transplantation (Day -30 to Day -8) through Month 24 after transplantation.

Arms and interventions

Patients receiving letermovir prophylaxisExperimental

CMV-seropositive hematopoietic stem cell transplant recipients receiving letermovir as primary prophylaxis and included in the NAViRe cohort. The study will describe overall and CMV-specific immune reconstitution, including its evolution during follow-up, using immunological and virological assessments.

Patients not receiving letermovir prophylaxisOther

Observational Cohort. CMV-seropositive hematopoietic stem cell transplant recipients included in the Cryostem cohort who did not receive letermovir as primary prophylaxis. The study will describe overall and CMV-specific immune reconstitution, including assessments before transplantation and at day 100 after transplantation.

Drugs: Letermovir

Other: Comparator

Sites

1 site in 1 country

  • Chu LimogesLimoges, France